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Background: Childhood obesity is associated with early cardiometabolic risk
(CMR), increased risk of adulthood obesity, and worse health outcomes. Leg
fat mass (LFM) is protective beyond total fat mass (TFM) in adults. However,
the limited evidence in children remains controversial.
Objective: We investigated the relationship between LFM and CMR factors
in youth.
Subjects: A total of 203 overweight/obese children, 7–17-yr-old, followed in
the Pediatric Clinic, Luxembourg.
Methods: TFM and LFM by dual energy x-ray absorptiometry and a detailed
set of CMR markers were analyzed.
Results: After TFM, age, sex, body mass index (BMI) Z-score, sexual
maturity status, and physical activity adjustments, negative significant partial
correlations were shown between LFM and homeostasis model assessment of
insulin resistance (HOMA) (variance explained: 6.05% by LFM*; 7.18% by
TFM**), fasting insulin (variance explained: 5.71% by LFM*; 6.97% by
TFM**), triglycerides (variance explained: 3.96% by LFM*; 2.76% by
TFM*), systolic blood pressure (variance explained: 2.68% by LFM*; 4.33%
by TFM*), C-reactive protein (variance explained: 2.31% by LFM*; 4.28% by
TFM*), and resistin (variance explained: 2.16% by LFM*; 3.57% by TFM*).
Significant positive partial correlations were observed between LFM and
high-density lipoprotein (HDL) cholesterol (variance explained: 4.16% by
LFM*) and adiponectin (variance explained: 3.09% by LFM*)
(*p-value < 0.05 and **p-value < 0.001). In order to adjust for multiple
testing, Benjamini–Hochberg method was applied and the adjusted
significance level was determined for each analysis. LFM remained significant
in the aforementioned models predicting HOMA, fasting insulin, triglycerides,
and HDL cholesterol (Benjamini and Hochberg corrected p-value < 0.01).
Conclusions: LFM is protective against CMR in children, at least in terms of
insulin resistance and adverse blood lipid profiles.
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A total of 250 million children are overweight or
obese in the world (1). This is a major public health
concern because child overweight/obesity, specifically
trunk, abdominal, and visceral excess adipose tissues,
associate with early metabolic and cardiovascular (CV)
risk factors and diseases in young people (2–7).
Pediatric obesity and cardiometabolic risk (CMR)
are associated with an increased risk for adulthood
obesity and related health outcomes as well (8–11).
In adults, leg fat seems to be protective beyond total
fat mass (TFM) and trunk fat as assessed by dual
energy x-ray absorptiometry (DXA) (12). Indeed, some
studies have found leg fat to be protective beyond
TFM and trunk fat against impaired glucose and lipid
metabolism, insulin action, arterial pressure regulation,
a less favorable inflammatory profile, and even vascular
damages and coronary artery risk and diseases (13–20).
Actually, gluteofemoral adipose tissue seems to have
a specific entrapment, storage, and low rate release of
fatty acids in adults, protecting from excessive ectopic
fat exposure and accumulation, in particular at the
level of visceral organs and muscle (21). Furthermore,
a favorable leptin and adiponectin profile is associated
with the lower body fat depots in adults independent
of total adiposity (19). In children, however, only
scarce body composition studies have been performed
in order to analyze the relationship between CMR
factors and lower limbs fat as assessed by DXA. Three
teams have reported on the DXA trunk vs. lower
limbs fat distribution effect by means of the android
to gynoid fat ratios [(L1–L4 fat mass area/lower
limbs fat)] (22), (fat mass area from the ilium to the
mandible/lower body fat from the ilium) (23), and/or of
the [(subscapular + waist)/(hip + thigh) fat mass] body
fat distribution index (24). A fourth study assessed the
relationship between the CMR factors and the (DXA-
leg fat/total body fat) percentage (25). However, these
studies produced inconsistent results with regard to
the relationship between the aforementioned adiposity
indices and the CMR factors. Furthermore, android
to gynoid body fat ratios describe general body fat
distribution and therefore cannot differentiate between
trunk and leg fat effects. Finally, except for the
study conducted by Teixeira et al. (26), none of these
studies have assessed the protective role of leg fat
beyond overall adiposity in childhood, and/or beyond
visceral adipose tissue (VAT), also recognized as an
independent metabolic and CV risk factor (6). Teixeira
et al. (26) attempted to define the role of leg fat
independent of general adiposity in children, but the
models developed by the authors were likely invalid
because of a high multicollinearity observed between
total and regional body fat measurements. Previous
studies are also limited to American, Indian, or French
populations, and conclusions may not be extrapolated
to other populations (20, 22–26).
In this study, we aim to analyze the relationship
between DXA leg fat measurements and CMR factors
in Luxembourg children and adolescents, independent
of overweight, obesity, and visceral adiposity.
Methods
Subjects
A total of 203 overweight and obese Caucasian
children, 7–17 yr old and frequenting the Diabetes
& Endocrinology Care Pediatric Clinic (Centre
Hospitalier de Luxembourg), agreed to participate,
with personal and parental informed consent, between
September 2006 and June 2008. Exclusion criteria
were diseases able to affect body composition such
as Prader Willi syndrome, hypoparathyroidism, leptin
deficiency, and/or Laurence Moon Biedl syndrome.
The study was approved by the CNER (National
Ethics Committee of Research) and authorized by
the National Commission for Data Protection. The
study was performed according to the Declaration of
Helsinki.
DXA measurements
Conventionally predefined TFM and leg fat mass
(LFM) were assessed by DXA, using a Hologic®
QDR4500W densitometer (Hologic Inc., Waltham,
MA, USA). Leg fat area was delineated by three
standard DXA cut lines: the angled line bisecting the
femoral neck below the pelvis, the vertical line lateral
to the leg and going on until the heel (until the floor),
and a second vertical line linking the pubic symphysis
to the toes (to the floor) (27).
Magnetic resonance imaging analysis
VAT was assessed by magnetic resonance imaging
(MRI) using a 1.5-T magnet (GE Signa HDXT
system, GE Medical Systems, Milwaukee, WI, USA).
Eight L4–L5-level centered and contiguous images,
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slice thickness = 10 mm, were performed by the
two-dimensional T1-weighted gradient echo pulse
sequence (repetition time = 120 ms, echo time = 4
ms, flip angle = 90◦, number of excitations = 1,
field of view = 48 cm, time of acquisition = 13 s,
matrix = 512 × 224, eight channels phased array body
coil). A semi-quantitative method developed in ImageJ
(U. S. National Institutes of Health, Bethesda, MD,
USA) (28), shown to provide good intra- and inter-
raters reproducibility (29), was used to calculate the
VAT area. After loading the L4–L5-MRI-axial-section
into ImageJ, a macro was executed to (i) automatically
delineate the total body section using binary conversion
and holes filling, (ii) define total adipose tissue by rater-
defined threshold, (iii) delineate manually the visceral
and non-subcutaneous adipose tissue sections using
adjustable predefined masks, and (iv) automatically
quantify the VAT area. Only abdominal MRI measures
were used for the analysis. Leg fat measures by MRI
were not available for comparison.
Anthropometric and clinical measurements
Height, weight, and waist circumference (measured
midway between the lower rib and the iliac crest) were
assessed by one trained examiner, according to the
Lohmann recommendations (30). Body mass index
(BMI) Z-scores were calculated using the Dutch L, M,
and S values (31) (National LMS data are unavailable)
and the free LMS Growth software and method
developed by Tim Cole (32). Established overweight
and obesity thresholds correspond to the 91th (91.496)
and 99th (99.350) percentiles in boys, respectively, to
the 89th (89.083) and 98th (98.644) percentiles in girls
(31, 32). Systolic (SBP) and diastolic (DBP) blood
pressures were measured in the sitting position with an
aneroid sphygmomanometer (Welch AL, Milwaukie,
OR, USA). The average of three readings was used.
BP Z-score was determined (33). The Tanner stages
were used to assess the sexual maturity status. We also
investigated the weekly number of hours which every
participant spends practicing physical activities.
Biological assessment
Fasting glucose, triglycerides, high-density lipopro-
tein (HDL) cholesterol, and low-density lipoprotein
(LDL) cholesterol were measured with Roche reagents
on a P module of Roche Modular (Basel, Switzer-
land). For the determination of C-reactive protein
(CRP), an Olympus latex reagent was used on the
same P module of a Roche Modular. Fasting insulin
was measured by chemiluminescent assay on Siemens
Immulite 2000 (Deerfield, IL, USA), whereas fibrino-
gen was determined on Stago Compact (Asnie`res sur
Seine, France). Leptin, adiponectin, and resistin were
measured with enzyme-linked immunosorbent assay
kits provided by Mediagnost (Reutlingen, Germany).
Homeostasis model assessment of insulin resistance
[HOMA IR = fasting insulin (μU/mL) × fasting glu-
cose (mmol/L)/22.5] was calculated. All blood samples
were taken after 12 h fasting.
Statistical analyses
Statistical analyses were performed using SPSS® for
Windows (17.0). Normal distribution of data was
checked using the Kolmogorov–Smirnov test and
confirmed by a visual inspection of the frequency
histograms and Q–Q plots. Skewed variables (i.e.,
triglycerides, HDL cholesterol, fasting insulin, HOMA
IR, CRP, fibrinogen, adiponectin, leptin, and resistin)
were log transformed. Descriptive data were provided
as mean ± SD and/or percentages. Student’s t and chi-
squared tests were used to compare sex differences in
means and percentages. To assess the distinctive LFM,
TFM, and VAT aptitudes to predict CMR factors,
univariate regressions were performed between LFM,
TFM, and/or VAT, and each laboratory biological
measurement. Partial correlations (r partial) were
assessed. To determine the potential protective effect
of LFM beyond TFM, we performed multivariable
linear regressions between fasting glucose, fasting
insulin, HOMA IR, triglycerides, HDL cholesterol,
LDL cholesterol, CRP, adiponectin, leptin, resistin,
SBP, DBP, and fibrinogen as dependent and LFM
and TFM as independent variables. Comparative
models were applied to assess the relationship between
VAT and the aforementioned biological parameters,
as well as the additional effect of LFM to both
VAT and TFM. Each univariate and/or multivariable
model was age-, sex-, sexual maturity status-, BMI
Z-score-, and physical activity-adjusted. Results with
a p-value < 0.05 were initially considered statistically
significant. In order to evaluate the effect of multiple
testing, the Benjamini–Hochberg adjusted p-values
were calculated, and the adjusted significance level
was determined for each set of analyses (34). The
tolerance of each variable was tested in order to
assess inter-variables multicollinearity and allow the
inclusion of the variables in the models. Tolerance
is the proportion of the variance of a variable in
the multivariable models that is not accounted for
by other independent variables. A minimal tolerance
of 0.1 was set for the variables to be included in
the models, as recommended by SPSS® for Windows
Version 17.0.
Results
General characteristics are detailed in Table 1.
Pediatric Diabetes 2015 3
Samouda et al.
Table 1. Participants characteristics
Girls Boys All children
Mean ± SD Mean ± SD Mean ± SD
Age (yr) 12.2 ± 2.5 11.8 ± 2.4 12.0 ± 2.4
BMI (kg/m2) 28.5 ± 5.6 28.2 ± 4.9 28.3 ± 5.3
BMI Z-score 2.42 ± 0.58 2.68 ± 0.53* 2.54 ± 0.57
Waist circumference (cm) 83.8 ± 12.4 86.5 ± 11.5 85.1 ± 12.0
TFM (kg) 32.5 ± 14.3 30.1 ± 10.9 31.4 ± 12.8
LFM (kg) 12.7 ± 6.2 11.2 ± 4.2 12.0 ± 5.4
VAT (cm2) 35.0 ± 18.0 40.2 ± 19.1 37.4 ± 18.7
Fasting glucose (mg/dL) 86.2 ± 6.8 86.9 ± 6.2 86.5 ± 6.5
Fasting insulin (mUI/L) 17.5 ± 8.5 14.8 ± 8.3* 16.2 ± 8.5
HOMA IR 3.76 ± 1.98 3.21 ± 1.87* 3.50 ± 1.94
Triglycerides (mg/dL) 98.4 ± 58.4 90.0 ± 51.1 94.3 ± 55.1
HDL cholesterol (mg/dL) 54.4 ± 12.7 52.9 ± 12.1 53.7 ± 12.4
cLDL cholesterol (mg/dL) 92.3 ± 29.0 93.0 ± 28.2 92.6 ± 28.6
SBP (mmHg) 117 ± 12 118 ± 14 117 ± 13
SBP Z-score 0.99 ± 1.04 0.91 ± 1.10 0.95 ± 1.07
DBP (mmHg) 71 ± 9 72 ± 8 72 ± 9
DBP Z-score 0.75 ± 0.78 0.81 ± 0.64 0.78 ± 0.71
CRP (mg/L) 2.9 ± 4.1 3.2 ± 3.8 3.1 ± 4.0
Fibrinogen (g/L) 3.7 ± 0.7 3.6 ± 0.6 3.6 ± 0.7
Adiponectin (μg/mL) 8.0 ± 4.7 7.8 ± 4.5 7.9 ± 4.6
Leptin (ng/mL) 38.7 ± 23.1 27.4 ± 16.1** 33.3 ± 20.8
Resistin (ng/mL) 5.3 ± 2.2 5.1 ± 2.0 5.2 ± 2.1
Percentages Percentages Percentages
Overweight 36.8 35.1 36.0
Obese 63.2 64.9 64.0
BMI, body mass index; cLDL, low-density lipoprotein cholesterol; CRP, C-reactive protein; DBP, diastolic blood pressure;
HDL, high-density lipoprotein; HOMA IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein;
LFM, leg fat mass; SBP, systolic blood pressure; SD, standard deviation; TFM, total fat mass; VAT, visceral adipose tissue.
*p-value < 0.05 and **p-value < 0.001.
Prediction of CMR factors using leg fat only
After age, sex, BMI Z-score, sexual maturity status,
and physical activity adjustments, and considering
the Benjamini–Hochberg adjusted p-values, signif-
icant positive partial correlations were observed
between LFM and leptin (p-value < 0.004), VAT
and triglycerides, as well as VAT and CRP (p-value
< 0.04), TFM and leptin (p-value < 0.004). Significant
negative partial correlations were observed between
VAT and HDL cholesterol as well as between VAT
and adiponectin (p-value < 0.04) (Table 2).
Prediction of CMR factors using models
associating LFM with TFM and/or with VAT
After combination of LFM and TFM, and adjust-
ments by age, sex, BMI Z-score, sexual maturity status,
and physical activity, significant negative partial cor-
relations were noticed in the multivariable models
between LFM and fasting insulin, HOMA, triglyc-
erides, CRP, resistin concentrations, and SBP Z-score.
Variances (V) explained by LFM ranged between 2.16
and 6.05% in these cases: resistin (V = 2.16%), CRP
(V = 2.31%), SBP Z-score (V = 2.68%), triglycerides
(V = 3.96%), fasting insulin (V = 5.71%), and HOMA
(V = 6.05%) (p-values < 0.05).
When significant positive partial correlations were
observed by LFM in the multivariable models,
variance explained by LFM was 3.09% for adiponectin
and 4.16% for HDL cholesterol concentrations (p-
values < 0.05). Within this framework, in the same
multivariable models, partial correlations linking up
TFM to the aforementioned biological variables were
significantly positive for fasting insulin, HOMA,
triglycerides, SBP Z-score, CRP, and resistin but
not significant in relation to HDL cholesterol and
adiponectin. TFM partially explained variance was
of the order of 7.18% to predict HOMA IR (p-
value < 0.001), 6.97% to predict fasting insulin (p-
value < 0.001), 4.33% for SBP Z-score (p-value < 0.05),
4.28% for CRP (p-value < 0.05), 3.57% for resistin
(p-value < 0.05), and 2.76% for triglycerides (p-
value < 0.05) prediction.
The global explained variances of the models
ranged from 50.5 (fasting insulin) to 10.9%
(adiponectin) (Table 3). After adjusting for the
Benjamini–Hochberg’s multiple testing method, LFM
remained significant in the models predicting fasting
insulin, HOMA, triglycerides, and HDL cholesterol
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Table 2. Pearson’s correlation coefficients (R) between leg fat mass, respectively visceral fat, total fat mass, and
cardiometabolic risk factors (age, sex, BMI Z-score, sexual maturity status, and physical activity adjustments)
LFM VAT TFM
R2 model r partial LFM R2 model r partial VAT R2 model r partial TFM
Fasting glucose 0.054 −0.057 0.059 −0.081 0.051 −0.003
Fasting insulin† 0.468**‡ 0.003 0.459**‡ 0.080 0.475**§ 0.116
HOMA IR† 0.460**‡ −0.005 0.449**‡ 0.059 0.467**§ 0.110
Triglycerides† 0.148**‡ −0.118 0.174**‡ 0.233*¶ 0.137**§ −0.036
HDL cholesterol† 0.125**‡ 0.193* 0.109*‡ −0.228*¶ 0.104*§ 0.117
LDL cholesterol 0.021 −0.116 0.011 0.017 0.017 −0.094
SBP Z-score 0.207**‡ 0.060 0.221**‡ 0.120 0.220**§ 0.142
DBP Z-score 0.166**‡ −0.034 0.170**‡ 0.177* 0.165**§ 0.017
CRP† 0.151**‡ 0.086 0.236**‡ 0.266**§ 0.169**§ 0.166*
Fibrinogen† 0.160**‡ 0.172* 0.176**‡ 0.042 0.157**§ 0.162*
Adiponectin† 0.098*‡ 0.175* 0.153**‡ −0.240*¶ 0.081* 0.111
Leptin† 0.612**‡ 0.392**§ 0.569**‡ −0.071 0.614**§ 0.398**§
Resistin† 0.087*‡ 0.057 0.086*‡ 0.055 0.100* 0.132
BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOMA IR, homeostasis model
assessment of insulin resistance; LDL, low-density lipoprotein; LFM, leg fat mass; SBP, systolic blood pressure; TFM, total
fat mass; VAT, visceral adipose tissue.
*p-value < 0.05 and **p-value < 0.001.
†Log-transformed variables.
‡Benjamini and Hochberg corrected p-value < 0.01.
§Benjamini and Hochberg corrected p-value < 0.04.
¶Benjamini and Hochberg corrected p-value < 0.004.
(Benjamini and Hochberg corrected p-value < 0.01).
TFM remained significant in the models predicting
fasting insulin, HOMA, SBP Z-score, CRP, and resistin
(Benjamini and Hochberg corrected p-value < 0.02)
(Table 3). No lower tolerance than 0.1 was observed
in the models 1 and 2 combining LFM and TFM,
excluding the collinearity between the variables
(Table 3).
When associated at the same time with VAT
and TFM (after age, sex, BMI Z-score, sexual
maturity status, and physical activity adjustments)
and according to the Benjamini–Hochberg adjustment
method, LFM was significantly correlated with fasting
insulin and HOMA (negative r partial) (p < 0.007).
On the other hand, VAT did not show any significant
contribution in the tripartite model associating LFM,
TFM, and VAT. Finally, a lower tolerance than
0.1 was observed in this third model, suggesting a
certain multicollinearity between VAT, LFM, and
TFM (Table 4).
Discussion
This study suggests a protective effect of LFM,
beyond overall adiposity and from childhood onwards,
against potential CMR development because of
overweight and obesity. Indeed, LFM as assessed
by DXA showed statistically significant and inverse
relationships with fasting insulin, HOMA IR,
triglycerides, SBP, CRP, and resistin; significant
positive relationship with HDL cholesterol and
adiponectin in 7- to 17-yr-old overweight and obese
Luxembourg youths; and a significant protective
relationship against insulin resistance and adverse
blood lipid profiles, even after adjusting the
significance levels according to the Benjamini–
Hochberg method.
Moreover, variances explained by LFM were rather
substantial in the multivariable models and could reach
6.05% in some cases, for instance to predict HOMA
IR, with 7.18% variance explained by TFM. We also
noticed that variances explained by both TFM and
LFM were rather close in the multivariable models,
suggesting in case of high values of TFM that LFM
may be the key player protecting against CMR.
To our knowledge, none of the children-
related studies have shown such associations, except
for Staiano et al. (25) who observed an inverse associ-
ation between leg fat and triglycerides concentrations
only, after TFM adjustment. The authors however
examined the associations with leg fat percentages (leg
fat divided by whole body fat), whereas we investi-
gated the relationships between the absolute values of
LFM and CMR factors (after TFM adjustment in
both cases). This may be the reason why Staiano
et al. (25) did not observe significant relationships
between leg fat and the other CMR factors tested:
blood pressure, fasting triglycerides, HDL cholesterol,
glucose, insulin, and CRP. On the other hand, we
observed similar relationships to those highlighted in
the adult studies. Beyond the implication of TFM,
large LFMs were linked up to low triglycerides, LDL
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Table 3. Cardiometabolic risk prediction using models combining leg and total fat masses (age, sex, BMI Z-score, sexual
maturity status, and physical activity adjustments)
Model 1: LFM, TFM Model 2: VAT, TFM
R2
Model 1
r partial
LFM
r partial
TFM
R2
Model 2
r partial
VAT
r partial
TFM
Fasting glucose 0.067 −0.127 0.114 0.056 −0.074 0.005
Fasting insulin† 0.505**‡ −0.239*§ 0.264**¶ 0.462**‡ 0.078 0.095
HOMA IR† 0.499**‡ −0.246*§ 0.268**¶ 0.452**‡ 0.059 0.091
Triglycerides† 0.171**‡ −0.199*§ 0.166* 0.164**‡ 0.217*§ −0.047
HDL cholesterol† 0.141**‡ 0.204*§ −0.136 0.121*‡ −0.224*§ 0.117
LDL cholesterol 0.022 −0.073 0.025 0.014 0.018 −0.077
SBP Z-score 0.241**‡ −0.164* 0.208*¶ 0.228**‡ 0.112 0.146
DBP Z-score 0.177**‡ −0.117 0.113 0.164**‡ 0.167* 0.021
CRP† 0.188**‡ −0.152* 0.207*¶ 0.278**‡ 0.267**§ 0.225*§
Fibrinogen† 0.160**‡ 0.059 0.016 0.199**‡ 0.029 0.195*
Adiponectin† 0.109*‡ 0.176* −0.113 0.146*‡ 0.243*§ 0.091
Leptin† 0.617**‡ 0.083 0.110 0.632**‡ −0.103 0.378**§
Resistin† 0.119*‡ −0.147* 0.189*¶ 0.097*‡ 0.040 0.150*§
Tolerance 0.060 0.077
BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOMA IR, homeostasis model
assessment of insulin resistance; LDL, low-density lipoprotein; LFM, leg fat mass; SBP, systolic blood pressure; TFM, total
fat mass; VAT, visceral adipose tissue.
*p-value < 0.05 and **p-value < 0.001.
†Log-transformed variables.
‡Benjamini and Hochberg corrected p-value < 0.04.
§Benjamini and Hochberg corrected p-value < 0.01.
¶Benjamini and Hochberg corrected p-value < 0.02.
cholesterol, and fasting insulin levels, as well as to
high HDL cholesterol values in healthy European men
and women (14). LFM was also inversely associated
with blood pressure, plasma lipids, and glucose in
severely obese premenopausal women (13), with insulin
resistance and dyslipidaemia in postmenopausal older
women (16), with metabolic syndrome and inflam-
matory markers (CRP, interleukin 6, tumor necrosis
factor alpha, and plasminogen activator inhibitor-1)
in obese older adults (17), and with fasting and 2-
h post-load glucose levels in old men and women
(18).
A positive relationship between high adiponectin
levels and LFM, insulin sensitivity and better
glycaemic, lipid, and inflammatory profiles has also
been shown in adults, but not yet in youth.
Recent pediatric studies show that adiponectin DNA
methylation is reduced by the combined presence of
obesity and insulin resistance (19, 35). This certainly
highlights the potentially very important role of
high LFM levels in the adiponectin expression and
also in the regulation of the adiponectin-associated
complications in childhood overweight/obesity.
In our study, no significant associations were
observed with LFM after adjusting by both VAT
and TFM, except for fasting insulin and HOMA
IR. This is probably because of the multicollinearity
observed between the three fat’s compartments
and/or to the population’s sample which might be
too limited to provide answers to this question.
These issues probably need to be raised with larger
samples.
In addition, it is important to mention that when
we consider LFM as a single body composition
predictor, it appears significantly associated only with
leptin (after age, sex, BMI Z-score, sexual maturity
status, and physical activity adjustments). Therefore,
in our pediatric sample, the single LFM acts as the
TFM. This being said, previous pediatric studies did
not really investigate the implication of the single
LFM. Therefore, we have no element of comparison
with the literature, except for the Teixeira et al. (26)
study which showed that only apolipoprotein B was
significantly positively associated with LFM. No other
significant univariate partial correlations were indeed
observed between LFM and serum triglycerides, total,
LDL and HDL cholesterol, and apolipoproteins A-
I in this study (26). In fact, in the framework of
univariate analysis, the latest children-related studies
have examined the implication of at least a 2-DXA
parameter combination in the form of adiposity
indices. Aucouturier et al. (22) showed a positive
relationship between insulin resistance and an android
to gynoid fat ratio [(L1–L4 fat mass area/lower limbs
fat)] in French obese children and adolescents. Daniels
et al.(24) established unfavorable plasma lipid and
lipoprotein concentrations, blood pressure, and left
ventricular mass associations with a higher body fat
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Table 4. Prediction of cardiometabolic risk factors using models combining leg, visceral and total fat masses (age, sex, BMI
Z-score, sexual maturity status, and physical activity adjustments)
Model 3: LFM, VAT, TFM
R2
model 3
r partial
LFM
r partial
VAT
r partial
TFM
Fasting glucose 0.087 −0.179 −0.130 −0.166*
Fasting insulin† 0.490**‡ −0.229*§ −0.002 0.247*¶
HOMA IR† 0.485**‡ −0.246*§ −0.026 0.261**¶
Triglycerides† 0.191**‡ 0.178* 0.151 0.145
HDL cholesterol† 0.138*‡ 0.138 −0.170* −0.079
LDL cholesterol 0.015 −0.004 0.016 −0.027
SBP Z-score 0.233**‡ −0.075 0.081 0.127
DBP Z-score 0.167**‡ −0.066 0.136 0.068
CRP† 0.287**‡ −0.113 0.219* 0.195*
Fibrinogen† 0.201**‡ 0.050 0.044 0.033
Adiponectin† 0.166*‡ 0.155 −0.184* −0.105
Leptin† 0.633**‡ 0.053 −0.081 0.117
Resistin† 0.134*‡ 0.201* −0.030 0.243*¶
Tolerance 0.054 0.028 0.033
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HOMA IR,
homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; LFM, leg fat mass; SBP, systolic blood
pressure; TFM, total fat mass; VAT, visceral adipose tissue.
*p-value < 0.05 and **p-value < 0.001.
†Log-transformed variables.
‡Benjamini and Hochberg corrected p-value < 0.04.
§Benjamini and Hochberg corrected p-value < 0.01.
¶Benjamini and Hochberg corrected p-value < 0.007.
distribution index [(subscapular + waist)/(hip + thigh)
fat mass], in 9- to 17-yr-old Ohioan boys and girls (24).
Another DXA-android to gynoid fat ratio (fat mass
area from the ilium to the mandible/lower body fat
from the ilium) was positively associated with CMR
factors (lipid and insulin biomarkers) in 6- to 18-yr-old
Indian boys, in the study carried out by Jahagirdar et al.
(23). In adults, positive associations were observed
when authors investigated the impact of the single LFM
on CMR factors, as indicated in particular in the Van
Pelt et al. study (16). Also, authors showed a protective
effect of LFM (negative significant relationship) after
TFM adjustment (16). These findings in adults are
in several points similar to ours in children and
adolescents. Consequently, this study probably adds a
new dimension to the understanding of the relationship
between metabolically healthy obesity and body
composition in youth, through the protective role of
the LFM. This concept is well-established in adults
(36), but still to be defined among the youngest (37).
This study leads to the conclusion that, after taking
TFM into account, LFM may protect against CMR
factors in children and adolescents, at least in terms
of insulin resistance and hyperlipidaemia. This means
that different levels of LFM must be considered within
the framework of obesity prevention and therapeutic
processes in childhood.
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